Newron Pharmaceuticals - Edison Group

Overview
Price performance
Financials
Research
Sector insights
Thematics

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase III trial programme targeting schizophrenia.

Xadago is marketed as an add-on to levodopa therapy in PD. It is currently sold in Europe, Japan, the United States and other territories. Generic manufacturers have notified the FDA of their intention to file generic Xadago products. Newron is contesting these filings. Xadago is currently patent protected until at least 2027.

Latest Insights

View More

Healthcare |
Flash note

26.06.24

Newron Pharmaceuticals — Evenamide road to registration and beyond

Healthcare |
Flash note

14.05.24

Newron Pharmaceuticals — Evenamide potential for treatment of schizophrenia

Healthcare |
Flash note

01.05.24

Newron Pharmaceuticals — Evenamide notches up another win (study 008A)

Healthcare |
Update

20.03.24

Newron Pharmaceuticals — Evenamide set for a pivotal year

Sector

Healthcare

Equity Analyst

Soo Romanoff

Managing Director - Head of Content, Healthcare

Associate analyst

Jyoti Prakash

Analyst, Healthcare

Key Management

Marco Caremi

Executive VP of Business Development
Stefan Weber

CEO

Balance Sheet

Forecast net cash (€m)

29.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	4.3	(19.8)	45.5
Relative	0.8	(17.6)	33.4
52 week high/low	CHF11.0/CHF4.2

Financials

Newron is developing evenamide as an add-on therapy for poorly managed and treatment-resistant schizophrenia (TRS). In April/May 2024, Newron shared positive results from a Phase II/III trial (study 008A) in patients with schizophrenia who are taking antipsychotics but not classified as having TRS (primary and key secondary endpoints met). In January 2024, positive final results (12-month data for the full patient cohort) were announced for a Phase II trial (study 014/015) in TRS patients. Over 70% of patients experienced a clinically meaningful reduction in disease severity and 25% achieved remission. With these encouraging results in hand, Newron now intends to begin a potentially pivotal, multinational Phase III TRS programme (which could commence by end-2024). In its FY23 results, Newron recorded total revenue of €9.1m (up 48.6% y-o-y) for the period, primarily derived from Xadago-related royalty income.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2022A	6.1	(12.6)	(17.0)	(95.34)	N/A	N/A
2023A	9.1	(11.2)	(16.0)	(89.81)	N/A	N/A
2024E	24.3	2.1	(2.6)	(14.12)	N/A	N/A
2025E	27.1	3.3	(0.8)	(4.31)	N/A	N/A

Research

Flash note

Healthcare

20.03.23

Newron Pharmaceuticals — Positive top-line data to support clinical progress

Update

Healthcare

20.03.23

Newron Pharmaceuticals — A year ahead of clinical milestones for evenamide

Healthcare

Flash note

Newron Pharmaceuticals — Encouraging efficacy data from evenamide trial

Flash note

Healthcare

03.01.23

Newron Pharmaceuticals — Positive interim trial results in schizophrenia

Update

Healthcare

15.09.22

Newron Pharmaceuticals — Evenamide catalyst approaching

Flash note

Healthcare

07.06.22

Newron Pharmaceuticals — Evenamide efficacy still going strong after 52 weeks

Flash note

Healthcare

07.06.22

Newron Pharmaceuticals — Evenamide potential expanding in schizophrenia

QuickView

Healthcare

01.11.21

Newron Pharmaceuticals — Pivotal progress on schizophrenia therapy

Update

Healthcare

27.09.21

Newron Pharmaceuticals — Evenamide validation underway

Update

Healthcare

08.09.21

Newron Pharmaceuticals — Evenamide Phase III at 30mg twice daily dose

Update

Healthcare

18.05.21

Newron Pharmaceuticals — Long-term generic challenge to Xadago

Update

Healthcare

07.04.21

Newron Pharmaceuticals — Gate not yet open to Phase III

Update

Healthcare

29.03.21

Newron Pharmaceuticals — Dyskinesia deal delivered

Update

Healthcare

25.01.21

Newron Pharmaceuticals — Evenamide Phase II completes recruitment

QuickView

Healthcare

17.11.20

Newron Pharmaceuticals — Schizophrenia development adds value

edison tv

Healthcare

09.11.20

Newron Pharmaceuticals – EKF interview

Update

Healthcare

22.09.20

Newron Pharmaceuticals — Evenamide trial progressing well

Update

Healthcare

26.08.20

Newron Pharmaceuticals — Evenamide safety trial underway

Update

Healthcare

22.05.20

Newron Pharmaceuticals — Evenamide focus, Supernus to sell Xadago in US

Flash note

Healthcare

05.05.20

Newron Pharmaceuticals — Sarizotan fails to shine

Update

Healthcare

26.03.20

Newron Pharmaceuticals — Seeing STARS

Update

Healthcare

04.10.19

Newron Pharmaceuticals — Xadago slows, Evenamide lags but STARS ahead

Update

Healthcare

31.05.19

Newron Pharmaceuticals — Evenamide down but not out

Outlook

Healthcare

14.03.19

Newron Pharmaceuticals — Moving towards R&D inflection points

Update

Healthcare

11.10.18

Newron Pharmaceuticals — Next up – R&D day

Update

Healthcare

04.04.18

Newron Pharmaceuticals — 2018 focus on the CNS pipeline

Flash note

Healthcare

22.03.17

Newron Pharmaceuticals — Xadago receives FDA approval in PD

Update

Healthcare

13.03.17

Newron Pharmaceuticals — Marching into 2017

Outlook

Healthcare

02.09.16

Newron Pharmaceuticals — Update 2 September 2016

Flash note

Healthcare

31.03.16

Newron Pharmaceuticals — Update 31 March 2016

Flash note

Healthcare

18.03.16

Newron Pharmaceuticals — Update 17 March 2016

Update

Healthcare

15.03.16

Newron Pharmaceuticals — Update 14 March 2016

Update

Healthcare

21.12.15

Newron Pharmaceuticals — Update 20 December 2015

Further insights

insight

Healthcare

20.11.23

Newron Pharmaceuticals: EKF 2023 QuickView

insight

Healthcare

16.11.22

Deutsches Eigenkapitalforum (EKF) 2022 healthcare

insight

Consumer

26.07.22

Deutsches Eigenkapitalforum (EKF) 2022